Work

Su1862: QUANTIFYING THE BENEFIT–RISK TRADE-OFFS ADULT PATIENTS AND PROVIDERS ARE WILLING TO MAKE WHEN CONSIDERING ADVANCED THERAPIES FOR MODERATE TO SEVERE ULCERATIVE COLITIS: A DISCRETE CHOICE EXPERIMENT

Year: 2025

Type: conference-abstract

Source: Gastroenterology

DOI: 10.1016/s0016-5085(25)02923-3

Authors: Stefan Schreiber, Anthony Buisson, Meenakshi Bewtra, Peter Hur, Laura Panattoni, Brett Hauber, Natalie Land, Josh Coulter, Grace Gahlon, Xiang Guo, Christina C. Smith, Joseph C. Cappelleri, Karolina Wosik, Melissa Culhane Maravic, Alissa Walsh

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4411999686

Cites:

Cited by:

Related to: 10